All delegates are invited to attend the company
sponsored satellite symposia. The programmes for these satellite
symposia have been designed by the sponsoring companies and
have been vetted by the ECTS Scientific Programme Committee
to ensure balance, independence, objectivity and scientific
rigour. |
| |
| SATURDAY 23 MAY, 2009 |
 |
15:00 – 16:30 |
|
SATELLITE SYMPOSIUM 3
Bisphosphonate therapy: enhancing osteoporosis management
SUPPORTED BY THE ALLIANCE FOR BETTER BONE HEALTH (PROCTER
& GAMBLE PHARMACEUTICALS AND SANOFI-AVENTIS)
Traditional Viennese delicacies will be served to all attendees
prior to the symposium
Chair: Juliet Compston (Cambridge, UK) |
|
| |
|
INTRODUCTION
Juliet Compston (Cambridge, UK) |
|
|
|
ANALYSIS OF REGIONAL DIFFERENCES IN RISK FACTORS
AND FRAGILITY FRACTURES IN THE GLOW STUDY
Juliet Compston (Cambridge, UK) |
|
|
|
EFFECTIVENESS OF BISPHOSPHONATES ON CLINICAL
PRACTICE: NEW PERSPECTIVES
Serge Ferrari (Geneva, Switzerland) |
|
|
|
EVALUATION OF SAFETY IN LONG-TERM MANAGEMENT
OF OSTEOPOROSIS
Graham Russell (Oxford, UK) |
|
|
|
CONCLUSION AND Q&A SESSION
Juliet Compston (Cambridge, UK)
|
|
16:30 – 17:00 |
|
BREAK |
|
17:00 – 18:30 |
|
SATELLITE SYMPOSIUM 4
New perspectives for the treatment of osteoporosis: from bench
to bedside
SUPPORTED BY AMGEN
Chair: Stuart Ralston (Edinburgh, UK) |
|
| |
|
PREVENTING BONE LOSS BY TARGETING THE RANK/RANKL/OPG
PATHWAY
Serge Ferrari (Geneva, Switzerland) |
|
|
|
THE EFFECTS OF RANK LIGAND INHIBITION ON MARKERS
OF BONE TURNOVER
Richard Eastell (Sheffield, UK)
|
|
|
|
THE ROLE OF RANK LIGAND IN CONDITIONS OF HORMONE
ABLATION
Lorenz Hofbauer (Dresden, Germany)
|
|
| SUNDAY 24 MAY, 2009 |
|
18:00 – 19:30 |
|
SATELLITE SYMPOSIUM 5
The evidence builds for zoledronic acid: unparalleled comprehensive
fracture protection
SUPPORTED BY NOVARTIS
Webcast of satellite
Chair: René Rizzoli (Geneva, Switzerland) |
|
|
|
WELCOME AND INTRODUCTION
René Rizzoli (Geneva, Switzerland)
|
|
|
|
WEIGHING THE EVIDENCE IN POSTMENOPAUSAL OSTEOPOROSIS
Michael McClung (Portland, USA) |
|
|
|
COMPREHENSIVE OSTEOPOROSIS PROTECTION: BEYOND
THE PMO PATIENT
David Reid (Aberdeen, UK) |
|
|
|
EVIDENCE FROM HORIZON-RFT: THE ONLY RANDOMIZED
TRIAL IN POST-HIP FRACTURE SURGERY PATIENTS
Steven Boonen (Leuven, Belgium) |
|
| |
|
STATE-OF-THE-ART OSTEOPOROSIS TREATMENT: PANEL DISCUSSION
René Rizzoli (Geneva, Switzerland)
|
|
|
CLOSING REMARKS
René Rizzoli (Geneva, Switzerland) |
|
| MONDAY 25 MAY, 2009 |
|
18:00 – 19:30 |
|
SATELLITE SYMPOSIUM 6
Moving beyond conventional antiresorptives
SUPPORTED BY MSD
Chair: Roland Baron (Boston, USA) |
|
|
|
MUSCULOSKELETAL HEALTH AND VITAMIN D
Heike Bischoff-Ferrari (Zurich, Switzerland) |
|
|
|
ODANACATIB: NOVEL ANTIRESORPTIVE AGENT
Michael McClung (Portland, USA) |
|
|
|
NEW APPROACHES TO OSTEOANABOLIC THERAPY
John Bilezikian (New York, USA) |
|
| TUESDAY 26 MAY, 2009 |
|
|
18:00 – 19:30 |
|
SATELLITE SYMPOSIUM 7
New therapeutic options for postmenopausal women’s health
SUPPORTED BY ELI LILLY
Chair: Roberto Civitelli (St Louis, USA)
|
|
|
|
INTRODUCTION
Roberto Civitelli (St Louis, USA) |
|
|
|
EFFECTS OF ANTIRESORPTIVES AND BONE FORMING
AGENTS ON BONE QUALITY PARAMETERS
Mary Bouxsein (Boston, USA) |
|
|
|
Q&A SESSION |
|
|
|
TERIPARATIDE TREATMENT OF PRIMARY AND SECONDARY
OSTEOPOROSIS
Silvano Adami (Verona, Italy) |
|
|
|
Q&A SESSION |
|
|
|
IS THERE AN OPTION TO PREVENT OSTEOPOROTIC
FRACTURES AND INVASIVE BREAST CANCER WITH A SERM?
Silvia Migliaccio (Rome, Italy) |
|
|
|
Q&A SESSION |
|
|
|
WRAP UP |
|
|
|
Panel |
|
